ArticleNature2025
Tracking clonal evolution during treatment in ovarian cancer using cell-free DNA.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Tumor-intrinsic IFNγ signaling and niche adaptation drive early colonization in ovarian cancer metastasis.Nature communications · 2026Article
- Spatial Integration of Protein and Chromosomal States Reveals Early Copy-Number Changes and Genotype-Associated Immune Neighborhoods in Serous Ovarian Cancer Evolution.Cancer discovery · 2026Article
- Cancer drug response and resistance: molecular mechanisms and combating strategies.Signal transduction and targeted therapy · 2026Review
- Charting single-cell lineages with synthetic and natural barcodes.Nature reviews. Genetics · 2026Review
- Decoding DNA metabolism and its clinical relevance through the lens of high-throughput sequencing assays.Medical review (2021) · 2026Review
- Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer.NPJ precision oncology · 2026Article
- Evolution of oncogene amplification across 86,000 cancer cell genomes.bioRxiv : the preprint server for biology · 2026Article
- Molecular and cellular landscapes of the immune microenvironment and multiomic biomarker-sets in platinum-resistant recurrent ovarian cancers.Journal of ovarian research · 2026Review
- Concordance of Genomic Alterations in Ovarian Cancer Tissues and Circulating-Tumor DNA: A Pilot Study.International journal of molecular sciences · 2026Article
- Special Issue "Resistance to Therapy in Ovarian Cancers".International journal of molecular sciences · 2026Article
- Multidimensional tumor heterogeneity and its role in therapeutic resistance.Frontiers in immunology · 2026Review
- Immune-tumor cell ligand-receptor axes driving metabolic reprogramming and therapeutic resistance in cancer.Frontiers in immunology · 2026Review
- Anatomical precision in the omics era: a proposed framework for selective para-aortic lymphadenectomy in epithelial ovarian cancer.Frontiers in medicine · 2026Review
- Advances in ferroptosis research in ovarian cancer: molecular mechanisms and therapeutic perspectives.American journal of cancer research · 2026Review
- Targeting tumor transition windows.Exploration of targeted anti-tumor therapy · 2026Review
- Engineering immune-competent niches: strategies, applications, and translational hurdles in ovarian cancer organoid models.Frontiers in immunology · 2026Review
- Deciphering molecular pathways driving cancer invasion and metastasis: advances and therapeutic prospects.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Marc J WilliamsComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. william1@mskcc.org.ORCID 0000-0001-5524-4174
Ignacio Vázquez-GarcíaComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Grittney TamMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michelle WuComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-6889-8345
Nancy VariceDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0009-0008-5813-0808
Eliyahu HavasovComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hongyu ShiComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Duaa H Al-RawiComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-9218-6513
Gryte SatasComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hannah J LeesComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-1684-3075
Jake June-Koo LeeComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-1348-4094
Matthew A MyersComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-9337-5180
Matthew ZatzmanComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-5235-4116
Nicole RuskComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-2663-6288
Emily AliComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0009-0004-9372-0679
Ronak H ShahMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-9042-6213
Michael F BergerMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-3882-5000
Neeman MohibullahIntegrated Genomics Operation, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yulia LakhmanDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-3626-4502
Dennis S ChiDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nadeem R Abu-RustumDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Carol AghajanianDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Andrew McPhersonComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-5654-5101
Dmitriy ZamarinDepartment of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-0094-0161
Brian LoomisMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-1863-1199
Britta WeigeltDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-9927-1270
Claire F FriedmanDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-2621-8553
Sohrab P ShahComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. shahs3@mskcc.org.ORCID 0000-0001-6402-523X
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MTargeting Polθ to Overcome PARP Inhibitor Resistance in Homologous Recombination Deficient Breast CancerP50CA247749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Sarat Chandarlapaty, Simon N. Powell · 2020 to 2026
$16.3MExploiting markers of genomic instability in high-risk pre-invasive ovarian cancerR01CA281928 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Sohrab P Shah · 2023 to 2026
$2.9MPOTENTIATION OF ANTI-TUMOR IMMUNITY BY ONCOLYTIC VIRUS IN SITU VACCINATIONR01CA269382 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Dmitriy Zamarin · 2023 to 2026
$2.5MThe MSK Genomic Data Analysis Center for Tumor EvolutionU24CA264028 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SCHULTZ, NIKOLAUS, SHAH, SOHRAB P · 2021 to 2025
$2.1MSingle cell quantification of genomic instability in cancer as a determinant of therapeutic responseK99CA256508 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI WILLIAMS, MARC · 2021 to 2022
$200kNCI NIH HHS K99 CA256508NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA247749NCI NIH HHS R01 CA269382NCI NIH HHS R01 CA281928NCI NIH HHS U24 CA264028
Abstract
Emergence of drug resistance is the main cause of therapeutic failure in patients with high-grade serous ovarian cancer (HGSOC)
Indexed as
Cell-Free Nucleic AcidsClonal EvolutionClone CellsDrug Resistance, NeoplasmOvarian NeoplasmsAgedFemaleHigh-Throughput Nucleotide SequencingHumansMiddle AgedNeoplasm Recurrence, LocalSingle-Cell AnalysisWhole Genome SequencingCell-Free Nucleic Acids
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.